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Synopsis


The thesis entitled “Design, Synthesis and Biological Evaluation of Pyrrolo [2,1-c][1,4]benzodiazepine Hybrids and Benzothiadiazine Analogues” has been divided into four chapters. Chapter-I gives the introduction about cancer chemotherapy and novel DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines. Chapter-II deals with the design, synthesis and biological evaluation of novel benzoxazole, benzothiazole linked pyrrolo[2,1-c][1,4]benzodiazepines. Chapter-III provides the general introduction about tuberculosis and synthesis of pyridine, pyrazine derived benzothiadiazine analogues and their antimycobacterial activity. Chapter-IV comprises of two sections, section-A discusses the microwave enhanced reduction of nitro and azido arenes by using zinc-ammonium fomate system and synthesis of novel bioactive heterocycles like pyrrolo[2,1-c][1,4]benzodiazepines and 4(3H)-quinazolinones. While, section-B describes the synthesis of quinolines and their antibacterial, antiinflammatory studies.

Chapter-I: General introduction
Cancer is a broad term describing a diverse group of diseases sharing the common characteristic of abnormal cellular division that is not subject to normal growth controls. It is one of the most feared diseases due to a general perception that it is an indiscriminate and incurable affliction that insidiously attacks people of all cultures and ages. While cancer is an ancient disease, the inability to cure cancer has persisted despite rapid increases in social and economic improvements and impressive advances in scientific knowledge and medical techniques. The perception that the rate of cancer infections is increasing has recently been a matter for public discussion as has the recognition that the incidence of cancer is related to exposure to modern day chemicals. Though, the classical treatment of cancer, typically involves surgical removal of tumours or destruction by localized radiotherapy, chemotherapy is of utmost importance in order to ensure that all the malignant cells, including any meta-stats are destroyed.
Cancer chemotherapy may also improve both patient survival and well being to variable extent. Thus, there is no doubt an essential role for chemotherapeutic drugs in contemporary clinical oncology. The development of the area of anticancer drug discovery basically reflects an evolution from highly empirical approaches, based on serendipitous findings and testing of randomly selected compounds, to the current, more focused testing of natural products, rationally synthesized agents, and biological products against panels of well-characterized tumour cell lines or molecular targets. The major categories of chemotherapeutic agents are naturally occurring antitumor antibiotics, topoisomerase I and II inhibitors, and other miscellaneous compounds.
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are well known class  of antitumour antibiotics with sequence selective DNA binding ability that are derived from various Streptomyces species. The first pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotic anthramycin has been described by Leimgruber et. al. in 1963, and since then a number of compounds have been developed on PBD ring system leading to DNA binding ligands. Their mode of interaction with DNA has been extensively studied and it is considered unique as they bind within the minor groove of DNA. These compounds exert their biological activity by covalently binding to the C2-amino group of guanine residue in the minor groove of DNA through the imine or imine equivalent functionality at N10-C11 of the PBD moiety.



Chapter-II: Design, synthesis, DNA binding affinity and cytotoxicity of benzothiazole and benzoxazole linked pyrrolobenzodiazepines
The serendipitous discovery of the unique antitumour profile of 2-(4-aminophenyl)benzothiazole (A) arose when it was prepared as an intermediate in a project seeking routes to polyhydroxylated 2-phenylbenzothiazoles which were required for evaluation as potential tyrosine kinase inhibitors. An unusual feature of the activity of A against human breast cancer cell lines in vitro is the appearance of a characteristic biphasic dose-response relationship: the compound promotes cell death at sub-nanomolar concentrations but an increase in viable cell population occurs in the micromolar range. The structure activity relationships of this molecule has led to the discovery of most prominent anticancer active 2-(4-amnio-3-methylphenyl)benzothiazole (B), but this molecule is devoid of anticancer activity in vivo due to the formation of its 6-hydroxyl metabolite (C), which is inactive in vitro screening. To block the formation of this metabolite, a series of mono and di-fluoro derivatives of B have been prepared. From which surprisingly, 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole (D) emerged as the most potent analogue in in vitro evaluations. Intriguingly this agent, unlike the corresponding 6-fluoro isomer (E), abolished the biphasic dose-response relationship seen in vitro. Presumably, by inhibiting the formation of inactive exportable hydroxylated metabolites. Interestingly, the acetylated derivatives of A have also shown good anticancer activity.
The other class of benzothiazoles which are closely related to 2-(4-aminophenyl)benzothiazoles have also shown good antitumour activity. Remarkably, among an extended library of very close structural analogues, only a compound with a 2-(3,4-dimethoxyphenyl) group and a fluoro substituent in the benzothiazole ring, especially in the 5-position (F), is associated with exquisite bioactivity. The definitive molecular target underpinning the antitumour activity of this intriguing series has not been identified and mechanistically this new series of agents contrasts with the previously reported 2-(4-aminophenyl)benzothiazoles. Along with, iso-steric benzoxazoles have also been reported as anticancer molecules.

Recently, there has been growing interest in modifying and extending the recognition patterns of DNA binding ligands. Pyrrolo[2,1-c][1,4]benzodiazepine antitumour antibiotics bind covalently to the N2 of guanine in the minor groove of DNA. In the past few years, several PBD analogues have been designed and synthesized with the aim of finding related compounds showing better antitumour activity.
The objective of the present work is the synthesis of novel benzothiazole and benzoxazole linked pyrrolo[2,1-c][1,4]benzodiazepines, and study their DNA binding affinity as well as in vitro anticancer activity.
The precursors 1a, 1b have been prepared by the condensation of commercially available 2-aminothiophenol with 4-hydroxybenzaldehyde or vanillin in pyridine (Scheme 1).

The key intermediates 4a, 4b and 8 have been prepared as shown in Scheme 2. The synthesis of precursors 4a, 4b has been carried out by the condensation of 2-aminothiophenol with 4-nitrobenzoylchloride to give 2. This compound upon reduction gives 3, which upon coupling with bromoalkane acid chlorides yields 4a and 4b. The other precursor 8 has been prepared through Jacobson’s cyclization approach. The treatment of 4-fluoroaniline with 4-nitrobenzoyl chloride in pyridine gives 5. This compound has been further converted to its corresponding thio derivative 6 using Lawesson’s reagent by refluxing in toluene. Finally, the compound 6 has been cyclized to 7 by potassium ferricyanide according to Jacobson’s method followed by reduction and then coupling with bromopentanoyl chloride gives 8.




Synthesis of compounds 11a-b has been carried out by the condensation of 2-aminophenol with 4-benzyloxybenzaldehyde precursors to provide 9a-b. Compounds 9a-b have been converted to 10a-b by oxidative cyclization, which upon debenzylation affords 11a-b (Scheme 3).

Synthesis of C8-linked benzothiazole-PBD hybrids (20a-d) has been carried out by employing the commercially available vanillin. Oxidation of vanillin followed by benzylation and nitration by employing the literature methods provides the 4-benzyloxy-5-methoxy-2-nitrobenzoic acid (12). This has been further coupled to L-Proline methyl ester to afford the compound 13, which upon reduction with DIABAL-H produces the corresponding aldehyde 14, the aldehyde group of this product has been protected with EtSH/TMSCl to give 15. Compound 15 upon debenzylation affords (2S)-N-(4-hydroxy-5-methoxy-2-nitrobenzoyl) pyrrolidine-2-carboxaldehyde diethylthioacetal (16) which upon etherification by dibromoalkanes provides 17a-b. These compounds have been coupled to compounds 1a-b to produce the corresponding compounds 18a-d. These coupled nitrothioacetal intermediates 18a-d upon reduction with SnCl2.2H2O in methanol gives the aminothioacetal precursors 19a-d and these on deprotection by HgCl2/CaCO3 affords the desired PBD hybrids 20a-d (Scheme 4).
Compound 16 has been coupled to 4a, 4b and 8 to give corresponding 21b and 24 respectively. The compounds 21b and 24 on reduction with SnCl2.2H2O afford 22b and 25. Finally on deprotection with HgCl2/CaCO3 provide the corresponding imines 23b and 26. However, when 16 is coupled to 4a, the expected product 21a is not obtained and the precursor 4a is cyclized to product 27 (Scheme 5).



Synthesis of C8-linked benzoxazole-PBD conjugates (30a-b) has been carried out by employing the precursor 17b. The precursor 17b has been linked to 11a, 11b to give nitrothioacetal derivatives 28a, 28b and these nitro compounds upon reduction by SnCl2.2H2O in methanol gives the aminothioacetal precursors 29a-b which have been further deprotected by HgCl2/CaCO3 to afford the desired PBD-benzoxazole conjugates 30a, 30b (Scheme 6).


The DNA binding activity for these benzothiazole, benzoxazole linked PBD conjugates (20a-d, 23b, 26, 30a-b) has been examined by thermal denaturation studies using calf thymus (CT) DNA. Melting studies show that these compounds stabilize the thermal helix-coil transition (Tm) for the CT-DNA duplex at pH 7.0, incubated at 37 ºC. Among these analogues, 20c (Tm 4.1 C), 20d (Tm 6.2 C), 26 (Tm 2.1 C), 30a (Tm 4.1 C), 30b (Tm 4.2 C) possess good DNA binding affinity in comparison to DC-81 (Tm 0.3 C).
The restriction endonuclease inhibition studies carried out on these molecules also confirm the relative binding affinity of these new PBD hybrids (example 20d, Figure 1).

Figure 1. RED100-restriction endonuclease digestion assay for 20d

The C8-linked benzothiazole-PBD hybrids (20a-d) have also been evaluated against sixty human tumor cell lines derived from nine cancer types (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) as per NCI protocol.
The average Log10 GI50, Log10 TGI50 and Log10 LC50 values for compounds 20a-20d have been illustrated in Table 1.

Table 1. log10 GI50, log10 TGI and log10 LC50 mean graphs midpoints (MG_MID) of in vitro cytotoxicity data for the compounds 20a-d against human tumour cell lines.

Compound	Log10 GI50	Log10 TGI	Log10 LC50
20a	-6.30	-5.63	-4.75
20b	-6.07	-5.47	-4.67
20c	-6.15	-5.30	-4.35
20d	-7.09	-5.78	-4.37


Chapter-III: Design, synthesis and antimycobacterial activity of novel benzothiadiazines
Tuberculosis (TB), an air borne communicable disease, is the major cause of death from a single infectious agent and is one of the three world health organization priority infectious diseases. Recent estimates provided by the WHO suggest that around 8 million people contact TB annually, of whom 99% live in developing countries, with almost 2 million deaths. Thus M. tuberculosis is responsible for more human deaths than any other single infectious disease accounting for 7% of all deaths and 26% of all preventable deaths. It is further interesting that 50% of India’s population is reported to be tuberculin test positive. Thus, TB posses a major health hazard in India. These facts have made TB a topic of interest for many research groups in recent times.
This dreadful disease is reported to be caused by Mycobacterium tuberculosis, affecting any organ of the body and most commonly the lungs. This bacterium is transmitted exclusively by air especially when an individual with pulmonary TB coughs, a tiny droplet nuclei with TB bacterium is released into the air. This remains suspended in air and is viable for prolonged periods of time and infects the healthy individual who inhales it.
The organism is known to be specially equipped with a cell wall made up of covalently linked mycolic acids, arabinogalactans, peptidoglycans, ,-trehalose monomycolate and other related glycolipids. This cell wall becomes unique due to the presence of mycolic acids and the galactofuranoses of aranbinogalactan motifs has become an attractive target for anti-tubercular drug research. 
The drugs that have been used to fight TB include isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, p-aminosalicylicacid ethionamide cycloserine, capreomycin, kanamycin, thioacetazone, clofazimine etc. From these drugs streptomycin an amino glycoside antibiotic, isoniazid, rifampicin, ethambutol and pyrazinamide, inhibiting protein synthesis, mycolic acid synthesis, RNA polymerase, arabinogalactan synthesis, mutations respectively are considered to be the important front line anti TB drugs.
Apart from the unpleasant side effects, long course of treatment, toxicity and low cost affectivity, bacterial persistence and emergence of drug resistant strains have greatly complicated the current drug therapies. Therefore, new molecules like thiolactomycins, calanolide, clofazimine, nitroimidazoles, oxazolidinones and some fluoroquinolones  etc., have been developed.
Recently several benzothiadiazine analogues have attracted much attention towards antiviral, potassium channel openers. These are also known as antibacterial active molecules. Basing on this we have prepared a series of benzothiadiazines analogues and evaluated their antimycobacterial activity. The present work describes the synthesis and anti-tuberculosis activity of 1,2,4-benzothiadiazine 1,1-dioxides and also discusses efforts to develop the structure–activity relationship for this ring system.
The preparation of key intermediates 3-hydrazino-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxides (5a-e) and 3-chloro-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxides (4a-e) have been carried out by synthetic sequence illustrated in Scheme 1. The treatment of chlorosulfonyl isocyanate (2) with N-alkyl/aryl aniline (1a–e) in nitromethane, followed by cyclization with aluminium chloride, provides 4-alkyl/aryl-2H-1,2,4-benzothiadiazine-3(4H)-one 1,1-dioxide (3a–e). This upon chlorination with PCl5 affords 3-chloro-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxide (4a–e) which on treatment with hydrazine hydrate in chloroform yields 3-hydrazino-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxide (5a–e).
The target compounds 8a–m have been prepared by refluxing 3-hydrazino-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxides (5a–e) with acid chlorides  (nicotinoyl chloride hydrochloride, pyrazinoyl chloride, isonicotinoyl chloride hydrochloride and 6-chloro-nicotinoyl chloride 6a–d) in THF and triethylamine as a base. Alternatively the synthesis of 8a–m has been carried out by the reaction of 3-chloro-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxides (4a–e) with the corresponding hydrazides (pyrazine-2-carbohydrazide, nicotinic hydrazide and isonicotinic hydrazide 7a–c) in THF and triethylamine at room temperature (Scheme 2). However, the latter method has been found to be more versatile in terms of yields and reaction conditions. The other target compounds, 3-amino substituted-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxides 10a–c, have been prepared by N-substitution of amide precursors (pyrazinamide, 6-chloro-nicotinamide 9a–b) with 3-chloro-4-alkyl/aryl-4H-1,2,4-benzothiadiazine 1,1-dioxides (4d–e) in THF by employing sodium hydride (Scheme 3).








The in vitro antimycobacterial activity of compounds 8a-m, 10a-c has been evaluated by agar dilution assay. Among these molecules, only 8c, 8e, 8i, 8m have shown antimycobacterial activiy as shown in Table 1. Though, one of the analogue 8c has shown good in vitro antimyobacterial activity, but it has not shown in in vivo model.
Table 1. Antimycobacterial activity of 4H-1,2,4-benzothiadiazine 1,1-dioxide analogues against Mycobacterium sp.

	MIC (µg/mL)
Compd.	M. tb. H37RVATCC 27294	M. tb. Clinical isolates	M. a.ATCC 49601	M. i.ATCC 13950
		sensitive	resistant		
8c	0.5	0.5-1.0	0.5-2.0	2.0	2.0
8e	4.0	4.0-8.0	4.0-8.0	>16.0	>16.0
8i	8.0	8.0-16.0	8.0-16.0	16.0	8.0
8m	8.0	8.0-16.0	8.0-16.0	>16.0	>16.0
Isoniazid	0.25	0.125-0.25	8.0->16.0	8.0->16.0	8.0



Chapter-IV:
The development of new synthetic methodologies in organic synthesis is an important task, especially when considering the synthesis of either natural products or biologically active molecules of pharmaceutical or agrochemical significance. In many cases, the inspiration for developing the new methodology arises from a consideration of the structural features of such targets. Driven by the demands of industry and environmental considerations, much of this effort is aimed at defining new methods for the highly efficient and catalytic generation of such compounds. This can involve either new heterogeneous catalysts or microwave flow systems.

Section A: Microwave enhanced reduction of nitro and azido arenes to N-arylformamides employing Zn–HCOONH4: synthesis of 4(3H)-quinazolinones and pyrrolo[2,1-c][1,4]benzodiazepines
In recent years, microwave irradiation is very attractive tool for chemical applications and has become a widely accepted non-conventional energy source for performing organic synthesis. A large number of examples have been described in organic synthesis. Zinc under microwave irradiation and combination of zinc-ammonium formate system have been extensively studied for different synthetic transformations in organic synthesis. Basing on this, a methodology for the synthesis of N-arylformamides and 4(3H)-quinazolinones has been deveoped. 
The present work describes the synthesis of N-arylformamides and 4(3H)-quinazolinones under microwave irradiation by employing zinc and ammonium formate
Compounds N-arylformamides (2a-l) have been prepared by reducing nitro (1a-f) or azido arenes (1g-l) with zinc and ammonium formate under microwave irradiation (Scheme 1).

The compounds 4(3H)-quinazolinones (4a-d) have been prepared by reducing azido (3a-b) or nitro benzoic acids (3c-d) with zinc and ammonium formate under microwave irradiation (Scheme 2).





In the absence of microwave irradiation, the above system has been utilized for the synthesis of DNA interactive pyrrolo[2,1-c][1,4]benzodiazepines.
The final compounds (7a-c, 8a-c) have been prepared by employing the precursors 5a-c according to the Scheme 3. Azidobenzoyl pyrrolidine esters 5a-c have been treated with DIBAL-H to obtain the corresponding aldehydes 6a-c. These upon reductive cyclization with zinc and ammonium formate provides the corresponding pyrrolo[2,1-c][1,4]benzodiazepine imines 7a-c. Further, the treatment of 5a-c with this reagent system yields pyrrolo[2,1-c]benzodiazepine dilactams 8a-c.







Section B: Efficient synthesis of quinolines: bioactive studies
Quinoline derivatives represent the major class of heterocycles, and this ring system is present in a variety of natural products, especially in alkaloids. The quinoline skeleton is often used for the design of many synthetic compounds with diverse pharmacological properties. The structural core of quinoline has generally been synthesized by various conventional named reactions such as Skraup, Doebner-von Miller, Friedländer, Pfitzinger, Conrad-Limpach and Combes. However, among these methods, the protocol reported by Friedländer is one of the straightforward and practical procedure. This method is based on an acid or base catalyzed condensation followed by a cyclo-dehydration between 2-aminoaryl ketone and a second carbonyl compound containing a reactive -methylene group.
The present work describes the synthesis of Friedländer quinolines by using Al(OTf)3 under solvent-free conditions.




The above compounds have been condensed with our earlier 3-hydrazino-4H-1,2,4-benzothiadiazine 1,1-dioxides to study their biological activities. The present work describes the synthesis of benzothiadiazine fused quinolines and study of their antibacterial activities.
The compounds 8a-d have been prepared by condensation of benzothiazdiazines 7a-b and qunoline carboxylic acids 6a-b. The compounds 6a-b have been prepared by hydrolysis of quinoline carboxylates 4a-b.



Compounds 4a-b, 6a-b, 8a-d have been evaluated for antibacterial activity and antiinflammatory activity. However final compounds 8a-d alone have shown antibacterial activity with MIC value of 100-150 μg/mL. These compounds have also shown mild antiinflammatory activity.
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